Orthocell Ltd
ASX:OCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orthocell Ltd
Accrued Liabilities
Orthocell Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orthocell Ltd
ASX:OCC
|
Accrued Liabilities
AU$1.6m
|
CAGR 3-Years
23%
|
CAGR 5-Years
27%
|
CAGR 10-Years
18%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Accrued Liabilities
$4.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Race Oncology Ltd
ASX:RAC
|
Accrued Liabilities
AU$804.2k
|
CAGR 3-Years
57%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Accrued Liabilities
AU$52m
|
CAGR 3-Years
18%
|
CAGR 5-Years
155%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Accrued Liabilities
AU$1.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
33%
|
CAGR 10-Years
12%
|
|
Orthocell Ltd
Glance View
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.
See Also
What is Orthocell Ltd's Accrued Liabilities?
Accrued Liabilities
1.6m
AUD
Based on the financial report for Dec 31, 2025, Orthocell Ltd's Accrued Liabilities amounts to 1.6m AUD.
What is Orthocell Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
18%
Over the last year, the Accrued Liabilities growth was 68%. The average annual Accrued Liabilities growth rates for Orthocell Ltd have been 23% over the past three years , 27% over the past five years , and 18% over the past ten years .
